Smart science to improve lives™
Pharma

3D-PHAD™

Add to favourites

Highly pure, safe, and chemically stable, 3D-PHAD stimulates the immune system through the activation of TLR4, leading to the production of proinflammatory cytokines, CD4+ and CD8+ T-cells.

3D-PHAD is a synthetic analogue of monophosphoryl lipid A (MPLA.) Derived from Salmonella minnesota, MPLA has significant benefits for adjuvant systems. It can be used in combination with different antigens to achieve an effective vaccine. Its demonstrated potency allows for lower dose volumes.

3D-PHAD is part of our PHAD portfolio and is a 3-deacylated form of MPLA. Varying the number and positioning of acyl chains creates a variety of lipophile/hydrophile ratios that can be utilised by formulation scientists to better suit their lipid-delivery systems.

3D-PHAD has been used in vaccine research to develop more effective strategies that tackle the influenza virus and opioid overdose crisis.

To date, extensive preclinical testing has demonstrated the parity between 3D-PHAD and PHAD.

Determining what adjuvant is best suited to your needs requires a discussion. Contact us to start your journey today.

Our 3D-PHAD is manufactured according to cGMP guidelines for clinical development.

Product details

Chemical group

  • Synthetic Monophosphoryl Lipid A analogue

Administration route

  • Vaccine adjuvant

Market application

  • Human vaccines
  • Veterinary vaccines

Functions

  • Vaccine adjuvant

Physical form

  • Powder